表2. 影响骨髓增生异常综合征(MDS)发生白血病转化(LT)的单因素与多因素分析.
因素 | 单因素分析 |
多因素分析 |
||
HR(95%CI) | P值 | HR(95%CI) | P值 | |
年龄≥60岁 | 2.043(1.297~3.218) | 0.002 | 1.168(0.617~2.212) | 0.634 |
男性 | 1.320(0.820~2.125) | 0.252 | ||
HGB<100 g/L | 1.227(0.722~2.084) | 0.450 | ||
ANC<0.8×109/L | 1.318(0.810~2.142) | 0.266 | ||
PLT≥100×109/L | 0.935(0.578~1.512) | 0.785 | ||
外周血细胞2~3系减少 | 0.813(0.500~1.322) | 0.405 | ||
骨髓原始细胞比例 | ||||
<5% | 参照 | 参照 | ||
5%~10% | 6.721(3.854~11.720) | <0.001 | 4.587(2.214~9.504) | <0.001 |
>10% | 10.641(5.462~20.731) | <0.001 | 9.352(4.049~21.600) | <0.001 |
IPSS-R细胞遗传学差和极差 | 3.836(2.278~6.459) | <0.001 | 2.603(1.229~5.511) | 0.012 |
LDH>247 U/L | 1.370(0.836~2.245) | 0.212 | ||
MF-2/3级 | 3.106(1.584~6.091) | 0.001 | 2.461(0.934~6.482) | 0.068 |
基因突变数目≥3个 | 2.662(1.520~4.663) | 0.001 | 1.359(0.655~2.819) | 0.409 |
U2AF1突变 | 0.970(0.505~1.864) | 0.927 | ||
DNMT3A突变 | 3.199(1.575~6.497) | 0.001 | 4.507(1.889~10.753) | 0.001 |
TP53突变 | 3.487(1.651~7.365) | 0.001 | 1.714(0.668~4.397) | 0.263 |
ASXL1突变 | 0.919(0.418~2.016) | 0.832 | ||
RUNX1突变 | 1.411(0.608~3.275) | 0.423 | ||
NPM1突变 | 4.676(1.996~10.957) | <0.001 | 3.341(1.164~9.591) | 0.025 |
NRAS突变 | 3.260(1.303~8.153) | 0.012 | 1.792(0.564~5.695) | 0.323 |
SF3B1突变 | 0.561(0.204~1.546) | 0.264 | ||
TET2突变 | 2.307(0.834~6.379) | 0.107 |
注:ANC:中性粒细胞绝对计数;IPSS-R:修订版国际预后积分系统;MF:骨髓纤维化